>> Could it be that they will file for approval of the 3-dose regimen in Asia while aiming for a 2-dose regimen in the West? <<
I bet it's something like that. For the first P3 , it made sense to do a head-to-head 3-dose comparison study , and in many countries this single trial may be sufficient for registration. In the EU and US they'll need a 2nd trial , and they may as well go for the 2-dose regimen as it will be an added marketing tool. The just completed trial will be supportive of the upcoming P3 using only two doses.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.